Posted on

Finally: Parkinson disease: Spanish research team found two major keys of the neuroprotection and natural increase of dopamine

Ramón Cacabelos

Ramón Cacabelos, a world known expert in neurodegenerative disorders and genomic medicine, and his team have completed preclinical and clinical studies with a nutraceutical called AtreMorine. The exceptional results show that AtreMorine protects selectively dopaminergic neurons and significantly increases naturally the dopamine level in the organism and without any reverse effects.

Parkinson’s disease, with known symptoms as tremors, stiffness, slowness of movements, depression and other, is mainly due to the progressive degeneration of dopaminergic neurons. These dopaminergic neurons are quite rare in the brain and they die gradually.

An estimated loss of 5 to 10% of these neurons degenerate per decade in everybody’s brain and this process starts more or less at the age of 20. This degeneration occurs even more rapidly in persons affected by Parkinson’s disease and once the loss of these neurons reaches the critical 60-80% barrier, all known symptoms of this disease appear.

To produce dopamine, the body needs its precursor L-dopa. If L-dopa is given to the organism, it will transform it into dopamine. If the body can not produce enough dopamine through its dopaminergic neurons because too many of them died, then we give the synthetic drug L-dopa producing good results for an average of 3 to 10 years. But as we know, unfortunately, despite the very interesting and confirmed results on the symptoms, especially in the early phases, these conventional medical drugs are not able to cure and the destruction of the remaining dopaminergic neurons continues.

Professor Ramon Cacabelos and his team studied and developed during the last seven years this exceptional bioproduct which has significant performances over disorders due to the lack of dopamine which is the case of Parkinson’s disease.

This study was recently published in the “Journal of Genomic Medicine and Pharmacogenomics Scitcentral” with all references to the pre-clinical and clinical results of this nutraceutical whose scientific name is E-PodoFavalin-15999, distributed under the name AtreMorine.

The participants in this clinical study were divided into two groups: on one side the Parkinson patients being already in long-term treatment with classical antiparkinsonian drugs and on the other side Parkinson’s patients never being in a medical treatment against Parkinson.

The first remark was that 100% of patients without antiparkinson treatment had dramatic hypodopaminergic levels, with dopamine plasma below 20 pg / mL. This is far too less for the body and this makes it evident that it is important to take medical treatments in the case of Parkinson’s disease.

Respecting the other scientific results of this study, they were numerous, very promising and encouraging in both groups of patients giving significant solutions for Parkinson’s patients:

The scientific study reveals, that the first beneficial effect of AtreMorine is the selective protection of dopaminergic neurons, that means:

“so far, no remedy allowed to stop or decrease significantly the loss of dopaminergic neurons, but thanks to AtreMorine that is possible now.”


The second most important beneficial effect of AtreMorine for Parkinson patients, revealed in the study, is its ability to increase significantly levels of dopamine in the body thanks to the enormously rich content of natural L-DOPA (average concentration: 20mg/g).

The scientific study indeed showed that:

“A single dose of 5-10 grams of AtreMorine increases dopamine levels in average range by 500% – 4000% in 30 minutes, and its effects remain up to 12 hours, improving in parallel the cardinal symptoms of Parkinson’s disease: tremor, bradykinesia, and rigidity.”


The nutraceutical is made out of 100% natural plant extracts with a patented extraction method that protects the active principals. Another important factor the study showed, was the fact that the nutraceutical was tolerated by 100% of patients without any adverse effects.

AtreMorine has also shown other beneficial effects with a powerful regulation the noradrenaline and the hormones of the pituitary gland, such as prolactin and growth hormone which takes part in the control of supra-hypothalamic dopaminergic neurotransmission as mentioned in the study.

The noradrenaline, as well as the dopamine, are very important in the regulation of the mood of the persons. Many studies show that sadness and depression are regular phenomenon observed in almost 30% of patients with parkinson.

The study suggests that AtreMorine can contribute to:

  • Reduce the phenomenon “wearing off” or “end-of-dose deterioration” (observed essentially in the intermediate and advanced phases).
  • Help to improve the therapeutic effect of conventional antiParkinson drugs and delay the loss of long term response (from the initial to the advanced phase).
  • Reduce at the same time the short term and long term adverse effects and long duration (from the initial to the advanced phase).

The study reveals precisely that co-administration of nutraceutical AtreMorine with antiparkinsonian drugs, allows a reduction of the conventional medicine dose between 25 to 50%, with clinical benefits and significant reduction of short and long term adverse of these drugs. Consequently, patients could use antiparkinsonian drugs over a much longer period.

This is how this nutraceutical showed its utility in all stages of Parkinson’s disease (initial, intermediate and advanced stages). It could also be an option particularly for patients with serious adverse reactions and who can not take antiparkinson drugs or those having greater tolerance to natural products.

The promising results of this study suggests that AtreMorine contribute to significantly improve the lives of thousands of persons and their families nowadays. In addition to this, Atremorine could not not only help persons already suffering with parkinson’s disease and who need urgent help right now, but also help to prevent degeneration by persons exposed to a high level of pesticides for example, or those with medical family records for Parkinson’s disease.

Atremorine is situated first of all as a complement to the anti-parkinsonian drugs with their beneficial effects over the symptoms.

Other scientific articles on the nutraceutical are published on the websites of the following journals: “Journal of Nutrition & Food Sciences”; Clinical & Medical Biochemistry“;  “Predictive, Preventive and personalized Medicine & Molecular  Diagnostics” ; “Journal of Exploratory Research in Pharmacology”; “International journal of molecular science”; “Current pharmaceutical design”.

Note: Live Better Parkinson’s is a news page on Parkinson’s.

We shared this scientific article with researchers from some of the most important universities in the world in the peer review committee, as we share other breaking news, nice initiatives and other information on Parkinson’s disease.

Useful Links

  1. Von Campenhausen S, Bornschein B, Wick R, Bötzel K, Sampaio C, et al. (2005) Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol.15: 473-490.
  2. Zou YM, Liu J, Tian ZY, Lu D, Zhou YY (2015) Systematic review of the prevalence and incidence of Parkinson’s disease in the People’s Republic of China. Neuropsychiatr Dis Treat 11: 1467-1472.
  3. Muangpaisan W, Hori H, Brayne C (2009) Systematic review of the prevalence and incidence of Parkinson’s disease in Asia. J Epidemiol 19: 281- 293.
  4. Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T (2016) The Incidence of Parkinson’s Disease: A Systematic Review and Meta-Analysis. Neuroepidemiol 46: 292-300.
  5. Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA (2016) Time Trends in the Incidence of Parkinson Disease. JAMA Neurol.
  6. PringsheimT , Jette N, Frolkis A, Steeves TD (2014) The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 29:1583- 1590.
  7. Riedel O, Bitters D, Amann U, Garbe E, Langner I (2016) Estimating the prevalence of Parkinson’s disease (PD) and proportions of patients with associated dementia and depression among the older adults based on secondary claims data. Int J Geriatr Psychiatry.
  8. Moisan F, Kab S, Mohamed F, Canonico M, Le Guern M, et al. (2015) Parkinson disease male-tofemale ratios increase with age: French nationwide study and meta-analysis. J Neurol Neurosurg Psychiatry.
  9. Miller DB, O’Callaghan JP (2015) Biomarkers of Parkinson’s disease: Present and future. Metab 64:S40-S46.
  10. Katzenschlager R, Lees AJ (2002) Treatment of Parkinson’s disease: levodopa as the first choice. J Neurol 249: II19-24.
  11. Cacabelos R (2012) World Guide for Drug Use and Pharmacogenomics. Euro Espes Publishing, Corunna.
  12. Pahwa R, Lyons KE (2009) Levodopa-related wearing-off in Parkinson’s disease: identification and management. Curr Med Res Opin 25: 841-849.
  13. Bhidayasiri R, Hattori N, Jeon B, Chen RS, Lee MK, et al. (2015) Asian perspectives on the recognition and management of levodopa ‘wearingoff’ in Parkinson’s disease. Expert Rev Neurother 15: 1285-1297.
  14. Haaxma CA, Horstink MW, Zijlmans JC, Lemmens WA, Bloem BR, et al. (20015) Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson’s Disease. J Parkinsons Dis 5: 847-853.
  15. Rascol O, Perez-Lloret S, Ferreira JJ (2015) New treatments for levodopa-induced motor complications. Mov Disord 30:1451-1460.
  16. Stowe R, Ives N, Clarke CE, Deane K, van Hilten, et al. (2010) Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev 7: CD007166.
  17. Lertxundi U, Isla A, Solinis MA, DomingoEchaburu S, Hernandez R, et al. (2015) Anticholinergic burden in Parkinson’s disease in patients. Eur J Clin Pharmacol. 71: 1271-1277.
  18. Owolabi LF, Samaila AA, Sunmonu T (2014) Gastrointestinal complications in newly diagnosed Parkinson’s disease: A case-control study. Trop Gastroenterol 35: 227-231.
  19. Tran T, Brophy JM, Suissa S, Renoux C (2015) Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-ErgotDerived Dopamine Agonist Use in Patients with Parkinson’s Disease: A Systematic Review of Observational Studies. CNS Drugs 29: 985-998.
  20. Cacabelos R (2016) Bioactive extract obtained from Viciafaba and its use in the treatment and/or prevention of neurodegenerative diseases. European Patent EP16382138.
  21. Carrera I, Fernández-Novoa L, Sampedro C, Aliev G, Cacabelos R (2016) Dopaminergic neuroprotection with atremorine in Parkinson’s disease. Current Medicinal Chemistry. SciTech Central Inc. J Genomic Med Pharmacogenomics (JGMP) 26 Journal of Genomic Medicine and Pharmacogenomics 1(1): 1-26 Cacabelos R, Fernández-Novoa L, Alejo R, Corzo L, Alcaraz M, et al.
  22. Boomsma F, Alberts G, van Eijk L, Man in ‘t Veld AJ, Schalekamp MA (1993) Optimal collection and storage conditions for catecholamine measurements in human plasma and urine. Clin Chem 39: 2503- 2508.
  23. Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, et al. (2009) Standard Operating Procedures for Serum and Plasma Collection: Early Detection Research Network Consensus Statement Standard Operating Procedure Integration Working Group. J Proteome Res 8: 113-117.
  24. Bouloux P, Perrett D, Besser GM (1985) Methodological considerations in the determination of plasma catecholamines by high-performance liquid chromatography with electrochemical detection. Ann Clin Biochem 22: 194-203.
  25. Foti A, Kimura S, DeQuattro V, Lee D (1987) Liquid-chromatographic measurement of catecholamines and metabolites in plasma and urine. Clin Chem 33: 2209-2213.
  26. Cacabelos R, Cacabelos P, Torrellas C, Tellado I, Carril JC (2014) Pharmacogenomics of Alzheimer’s disease: novel therapeutic strategies for drug development. Methods Mol Biol. 1175: 323-556.
  27. Cacabelos R, Torrellas C, Carrera I (2015) Opportunities in Pharmacogenomics for the treatment of Alzheimer’s Disease. Future Neurology 10: 229-252.
  28. Cacabelos R, Torrellas C (2014) Epigenetic drug discovery for Alzheimer’s disease. Expert Opin Drug Discov 9: 1059-1086.
  29. Cacabelos R, Torrellas C (2015) Epigenetics of aging and Alzheimer’s disease: Implications for pharmacogenomics and drug response. Int J Mol Sci 16: 30483-30543.
  30. Cacabelos R, Torrellas C, Teijido O, Carril JC (2016) Pharmacogenetic considerations in the treatment of Alzheimer’s disease. Pharmacogenomics.
  31. Altmann V, Schumacher-Schuh AF, Rieck M, Callegari-Jacques SM, Rieder CR, et al. (2016) Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson’s disease. Pharmacogenomics 17: 481- 488.
  32. Jiménez-Jiménez FJ, Alonso-Navarro H, GarcíaMartín E, Agúndez JA (2016) Advances in understanding genomic markers and pharmacogenetics of Parkinson’s disease. Expert Opin Drug Metab Toxicol 12: 433-448.
  33. Kurzawski M, Białecka M, Droździk M (2015) Pharmacogenetic considerations in the treatment of Parkinson’s disease. Neurodegener Dis Manag 5: 27-35.
  34. Schumacher-Schuh AF, Rieder CR, Hutz MH (2014) Parkinson’s disease pharmacogenomics: new findings and perspectives. Pharmacogenomics 15: 1253-1271.
  35. Rieck M, Schumacher-Schuh AF, CallegariJacques SM, Altmann V, Schneider Medeiros M, et al (2015) Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson’s disease patients?. Pharmacogenomics 16: 573-582.
  36. Schumacher-Schuh AF, Altmann V, Rieck M, Tovo-Rodrigues L, Monte TL, et al. (2014) Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson’s disease patients. Pharmacogenomics J 14: 289-294.
  37. Rieck M, Schumacher-Schuh AF, Altmann V, Francisconi CL, Fagundes PT, et al. (2012) DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson’s disease patients. Pharmacogenomics 13: 1701-1710.
  38. Moreau C, Meguig S, Corvol JC, Labreuche J, Vasseur F, et al. (2015) Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson’s disease. Brain 138: 1271-1283.
  39. Cacabelos R, Fernández-Novoa L, Lombardi V, Kubota Y, Takeda M (2005) Molecular genetics of Alzheimer’s disease and aging. Meth Find Exp Clin Pharmacol 27: 1-573.
  40. Cacabelos R (2004) Genomic characterization of Alzheimer’s disease and genotype-related phenotypic analysis of biological markers in dementia. Pharmacogenomics 5: 1049-1105.
  41. Cacabelos R, Fernández-Novoa L, Corzo L, Amado L, Pichel V, et al. (2004) Phenotypic profiles and functional genomics in Alzheimer’s disease and in dementia with a vascular component. Neurol Res 26: 459-480.
  42. Cacabelos R (2008) Pharmacogenomics in Alzheimer’s disease. Meth Mol Biol 448: 213-357.